Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:FTTCVE:HEMCVE:IBTCVE:NSCICVE:RVV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFTTFederated Enhanced Treasury Income Fund$0.00$12.81▼$13.82N/AN/A24,050 shsN/AHEMHemostemixC$0.14C$0.11C$0.04▼C$0.43C$20.40M0.2413,602 shs81,445 shsIBTIBEX TechnologiesC$1.44C$1.44C$0.75▼C$1.45C$35.54M-0.0568,888 shs200 shsNSCINanalysis ScientificC$0.25-2.0%C$0.26C$0.25▼C$0.46C$27.70M0.7265,688 shs25,810 shsRVVRevive TherapeuticsC$0.08+14.3%C$0.08C$0.07▼C$0.25C$5.79MN/A93,085 shs212,852 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHEMHemostemix0.00%+3.70%+12.00%+33.33%+133.33%IBTIBEX Technologies0.00%0.00%0.00%0.00%0.00%NSCINanalysis Scientific0.00%-2.00%-2.00%-14.04%-38.75%RVVRevive Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFTTFederated Enhanced Treasury Income FundN/AN/AN/AN/AN/AN/AN/AN/AHEMHemostemixN/AN/AN/AN/AN/AN/AN/AN/AIBTIBEX TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ANSCINanalysis ScientificN/AN/AN/AN/AN/AN/AN/AN/ARVVRevive TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFTTFederated Enhanced Treasury Income Fund 0.00N/AN/AN/AHEMHemostemix 0.00N/AN/AN/AIBTIBEX Technologies 0.00N/AN/AN/ANSCINanalysis Scientific 0.00N/AN/AN/ARVVRevive Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFTTFederated Enhanced Treasury Income FundN/AN/AN/AN/AN/AN/AHEMHemostemixN/AN/AC$0.01 per share10.77C($0.10) per shareN/AIBTIBEX TechnologiesC$5.77M6.15C$0.92 per share1.56C$0.58 per share2.48NSCINanalysis ScientificC$39.47M0.70C$0.03 per share8.93C$0.21 per share1.17RVVRevive TherapeuticsN/AN/AC$0.03 per share3.18C$0.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFTTFederated Enhanced Treasury Income FundN/AN/A0.00N/AN/AN/AN/AN/AN/AHEMHemostemix-C$5.00M-C$0.03N/A∞N/AN/A37.07%-349.24%N/AIBTIBEX TechnologiesC$3.10MC$0.1211.52∞N/A53.78%21.95%6.42%N/ANSCINanalysis Scientific-C$12.93M-C$0.12N/A∞N/A-32.75%-38.02%-7.55%N/ARVVRevive TherapeuticsN/A-C$0.02N/A∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFTTFederated Enhanced Treasury Income FundN/AN/AN/AN/AN/AHEMHemostemixN/AN/AN/AN/AN/AIBTIBEX TechnologiesN/A3.11%N/AN/AN/ANSCINanalysis ScientificN/AN/AN/AN/AN/ARVVRevive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFTTFederated Enhanced Treasury Income FundN/AN/AN/AHEMHemostemix-55.070.040.48IBTIBEX Technologies11.066.244.93NSCINanalysis Scientific71.721.421.11RVVRevive TherapeuticsN/A6.146.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFTTFederated Enhanced Treasury Income FundN/AHEMHemostemixN/AIBTIBEX Technologies19.05%NSCINanalysis Scientific0.03%RVVRevive TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipFTTFederated Enhanced Treasury Income FundN/AHEMHemostemix10.43%IBTIBEX Technologies25.36%NSCINanalysis Scientific3.95%RVVRevive TherapeuticsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFTTFederated Enhanced Treasury Income FundN/AN/AN/ANot OptionableHEMHemostemixN/A145.73 millionN/ANot OptionableIBTIBEX TechnologiesN/A24.68 millionN/ANot OptionableNSCINanalysis Scientific249113.06 millionN/ANot OptionableRVVRevive TherapeuticsN/A72.41 millionN/ANot OptionableIBT, RVV, FTT, HEM, and NSCI HeadlinesRecent News About These Companies2025-06-26 | Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant ... - StockhouseJune 28, 2025 | stockhouse.comRevive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling OpportunityJune 26, 2025 | financialpost.comFRevive Therapeutics Ltd.June 4, 2025 | barrons.comRevive Therapeutics Advances Next-Gen Bucillamine for Critical Medical NeedsJune 4, 2025 | tipranks.comRevive Therapeutics Advances with Next-Generation Bucillamine DevelopmentJune 4, 2025 | financialpost.comFRevive Therapeutics Ltd.: Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent ExposureMay 13, 2025 | finanznachrichten.deRevive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent ExposureMay 12, 2025 | financialpost.comFRevive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent ExposureMay 12, 2025 | financialpost.comFRevive Therapeutics Ltd. (RVV.NE)April 18, 2025 | ca.finance.yahoo.comRevive Therapeutics Ltd.: Revive Therapeutics to Investigate Bucillamine's Potential in Cancer TreatmentApril 10, 2025 | finanznachrichten.deRevive Therapeutics to Investigate Bucillamine’s Potential in Cancer TreatmentApril 10, 2025 | financialpost.comFRevive Therapeutics Announces Acquisition of Molecular Hydrogen ProgramApril 1, 2025 | markets.businessinsider.comDiagnaMed Granted FDA Orphan Drug Designation for Molecular Hydrogen to Treat Amyotrophic Lateral SclerosisMarch 3, 2025 | markets.businessinsider.comRevive Therapeutics buys DiagnaMed’s molecular hydrogen intellectual propertyMarch 3, 2025 | greenmarketreport.comGRevive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent ExposureJanuary 8, 2025 | financialpost.comFRevive Therapeutics Ltd. (RVVTF)November 24, 2024 | finance.yahoo.comRevive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent ExposureNovember 3, 2024 | uk.finance.yahoo.comRevive Therapeutics provides update on research study of bucillamineNovember 1, 2024 | markets.businessinsider.comRevive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical CountermeasuresSeptember 18, 2024 | markets.businessinsider.comRevive Therapeutics Ltd. (RVV.CN)September 3, 2024 | ca.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonThese 3 Dividend Stocks Combine Strong Yields With UpsideBy Chris Markoch | June 20, 2025View These 3 Dividend Stocks Combine Strong Yields With Upside3 Safe Buy-and-Hold Dividend Stocks With Strong Balance SheetsBy Chris Markoch | July 1, 2025View 3 Safe Buy-and-Hold Dividend Stocks With Strong Balance SheetsValue vs Growth Ratio Hits Cycle Low—Top Value Picks to BuyBy Gabriel Osorio-Mazilli | June 30, 2025View Value vs Growth Ratio Hits Cycle Low—Top Value Picks to Buy3 Tightly-Held Growth Stocks Set Up for Short SqueezesBy Thomas Hughes | June 9, 2025View 3 Tightly-Held Growth Stocks Set Up for Short SqueezesIBT, RVV, FTT, HEM, and NSCI Company DescriptionsFederated Enhanced Treasury Income Fund NYSE:FTTFederated Premier Intermediate Municipal Income Fund (the Fund) is a diversified, closed-end management investment company. The Fund's investment objective is to provide current income exempt from federal income tax, including the federal alternative minimum tax (AMT). The Fund's portfolio of investments include various sectors namely transportation, special tax, hospital, education, public power, senior care, water and sewer, general obligation-local, industrial development bond/pollution control revenue and general obligation-state. The Fund invests in intermediate-term, tax-exempt municipal bonds diversified among states, sectors and issuers. Federated Investment Management Company is the advisor of the Fund.Hemostemix CVE:HEMC$0.14 0.00 (0.00%) As of 07/4/2025 10:34 AM EasternHemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.IBEX Technologies CVE:IBTC$1.44 0.00 (0.00%) As of 04/5/2024IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; collagen ELISAs for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides lyophilization services for making disposable medical device components; and custom fermentation and contract manufacturing services. It serves manufacturers of medical devices, quality control labs, low molecular weight heparin manufacturers, and academic research institutions. IBEX Technologies Inc. was incorporated in 1972 and is based in Montreal, Canada.Nanalysis Scientific CVE:NSCIC$0.24 -0.01 (-2.00%) As of 07/4/2025 03:08 PM EasternNanalysis Scientific Corp. engages in the development, manufacture, and sale of magnetic resonance products in the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: Nanalysis, RS2D, K'Prime, and Corporate. It offers nuclear magnetic resonance (NMR) spectrometers; software module packages; cutting-edge electronics components for precision analytical instruments; and services for its NMR technologies. It serves pharmaceutical, security, biotech, nutraceutical, chemical, food, materials, medical, and education industries. The company is headquartered in Calgary, Canada.Revive Therapeutics CVE:RVVC$0.08 +0.01 (+14.29%) As of 07/22/2019Revive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc. Revive Therapeutics Ltd. was incorporated in 2012 and is headquartered in Vaughan, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
